Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2026-02-04 00:00:00 ET · period of report 2026-02-02 · accession 0001628280-26-005582 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-04 | 2026-02-02 | ARQT | Matsuda Masaru | See Remarks | S - Sale | $25.28 | -40.6K | 134.1K | -23% | -$1.03M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-02 | S | D | 7,983 | $25.50 | 142,658 | D | — | — | (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2026-02-02 | S | D | 4,714 | $25.63 | 110,003 | D | — | — | (F6) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.56 to $25.74, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-02-02 | S | D | 19,379 | $25.24 | 114,717 | D | — | — | (F5) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.55 to $25.55, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-02-02 | S | D | 8,562 | $24.97 | 134,096 | D | — | — | (F4) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.50 to $25.42, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |